Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gynecologic Oncology
•
Brachytherapy
•
Medical Oncology
Is there still a role of brachytherapy in uterine cancer if intensity-modulated radiation therapy is available?
Answer from: Radiation Oncologist at Academic Institution
Yes. Brachytherapy is still more conformal than optimally planned IMRT.
Sign in or Register to read more
18304
Related Questions
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
Does being on maintenance pembrolizumab change how you manage patients with partial metabolic response on PET/CT 3 months after chemoradiation for cervical cancer?
Do you have concerns about the validity of the INTERLACE data, considering the long study recruitment period (10 years) and evolution of radiation techniques that have occurred during that time frame?
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
What strategies do you find helpful in advanced care planning with patients/families who are very "miracle" centered?
What are your top takeaways in Gyn Cancers from ASCO 2025?
Are there patient populations in whom you would consider using both induction chemotherapy and maintenance pembrolizumab for a patient with locally advanced cervical cancer?
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?